Discovery on Target

Discovery on Target (DOT) has evolved into a premier meeting place for the latest advancements in early drug discovery, drawing participation from a diverse group of scientists across academia, start-ups, biotechs, pharma, and investment firms. This annual event, held in Boston, brings together around 1000 attendees, featuring approximately 220 presentations, over 115 research posters, and nearly 100 exhibitors. The agenda covers a wide range of topics including 3D Models and NAMs in Drug Development, Synthetic Biology for Drug Discovery, Emerging Drug Targets, Small Molecules for Cancer, Antibodies Against Membrane Protein Targets, RNA and DNA Targeting, and AI/ML-Enabled Drug Discovery. Attendees can expect specialized sessions such as 'Know Your GPCR Molecule' and 'Drug Exposure at the Target', which highlight critical factors in drug development processes. The event spans four days and is designed to provide key insights into the successful discovery and development of novel therapeutics, whether they be small molecules, biologics, chimeras, or conjugates. This year, there is an expanded focus on GLP-1, MASH, obesity treatments, antibody-drug conjugates (ADCs), and small molecules that target DNA. Attendees have the opportunity to engage in meaningful networking with over 1100 experts in drug discovery through various formats including concurrent sessions, panels, breakout discussions, and one-on-one networking events. Notable speakers include the Chief Scientific Advisor from Novo Nordisk, who will present insights into next-generation drug discovery, and the Chief Innovation Officer from Frontier Medicines Corporation, who will discuss trends in the field. The event also emphasizes the importance of community and collaboration, inviting participants to join the growing DOT network to stay at the forefront of innovations in drug discovery.